Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5054-5060

  Smith, Peter A ^a   Romesberg, Floyd E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ARYLOMYCIN; BACTERIAL PROTEIN; CEFALEXIN; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; NATURAL PRODUCT; POLYMYXIN B; RIFAMPICIN; SIGNAL PEPTIDASE I; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL SECRETION SYSTEM; CELL DENSITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ESCHERICHIA COLI; GROWTH CURVE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PROTEIN TRANSPORT; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; SERINE ENDOPEPTIDASES; STAPHYLOCOCCUS AUREUS;

EID: 84866314697     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00785-12     Document Type: Article

References (53)

1. Bollenbach T, Quan S, Chait R, Kishony R. 2009. Nonoptimal microbial response to antibiotics underlies suppressive drug interactions. Cell 139:707-718.
2. Cirz RT, et al. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3:e176. doi:10.1371/journal.pbio.0030176.
3. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 8th ed. CLSI document M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Cole JN, et al. 2007. Role of group A Streptococcus HtrA in the maturation of SpeB protease. Proteomics 7:4488-4498.
5. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645. (Pubitemid 30412767)
6. Davies J, Spiegelman GB, Yim G. 2006. The world of subinhibitory antibiotic concentrations. Curr. Opin. Microbiol. 9:445-453. (Pubitemid 44397635)
7. Desvaux M, Parham NJ, Scott-Tucker A, Henderson IR. 2004. The general secretory pathway: a general misnomer? Trends Microbiol. 12:306-309. (Pubitemid 38829650)
8. Driessen AJ, Nouwen N. 2008. Protein translocation across the bacterial cytoplasmic membrane. Annu. Rev. Biochem. 77:643-667.
9. du Plessis DJ, Nouwen N, Driessen AJ. 2011. The Sec translocase. Biochim. Biophys. Acta 1808:851-865.
10. Elion GB, Singer S, Hitchings GH. 1954. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J. Biol. Chem. 208:477-488.
11. Farha MA, Brown ED. 2010. Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity. Chem. Biol. 17:852-862.
12. Foucaud-Scheunemann C, Poquet I. 2003. HtrA is a key factor in the response to specific stress conditions in Lactococcus lactis. FEMS Microbiol. Lett. 224:53-59. (Pubitemid 36830822)
13. Reference deleted.
14. Hall MJ, Middleton RF, Westmacott D. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11:427-433. (Pubitemid 13094077)
15. Heikkinen O, et al. 2009. Solution structure of the parvulin-type PPIase domain of Staphylococcus aureus PrsA - implications for the catalytic mechanism of parvulins. BMC Struct. Biol. 9:17. doi:10.1186/1472-6807-9-17.
16. Huber J, et al. 2011. F1-1351 - a novel lipoglycopeptide inhibitor of signal peptidase I synergizes with imipenem against MRSA: a new approach for developing an MRSA combination therapy. Annu. Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. http://www.icaac.org/.
17. Hyyrylainen HL, et al. 2010. Penicillin-binding protein folding is dependent on the PrsA peptidyl-prolyl cis-trans isomerase in Bacillus subtilis. Mol. Microbiol. 77:108-127.
18. Ince D, Hooper DC. 2003. Quinolone resistance due to reduced target enzyme expression. J. Bacteriol. 185:6883-6892. (Pubitemid 37444490)
19. Kohanski MA, Dwyer DJ, Wierzbowski J, Cottarel G, Collins JJ. 2008. Mistranslation of membrane proteins and two-component system activation trigger antibiotic-mediated cell death. Cell 135:679-690.
20. Kulanthaivel P, et al. 2004. Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I. J. Biol. Chem. 279:36250-36258. (Pubitemid 39128961)
21. Lee SH, et al. 2011. Antagonism of chemical genetic interaction networks resensitize MRSA to beta-lactam antibiotics. Chem. Biol. 18:1379-1389.
22. Lewenza S, Gardy JL, Brinkman FS, Hancock RE. 2005. Genome-wide identification of Pseudomonas aeruginosa exported proteins using a consensus computational strategy combined with a laboratory-based PhoA fusion screen. Genome Res. 15:321-329. (Pubitemid 40309397)
23. Liu J, et al. 2011. Synthesis and characterization of the arylomycin lipoglycopeptide antibiotics and the crystallographic analysis of their complex with signal peptidase. J. Am. Chem. Soc. 133:17869-17877.
24. Luke I, Handford JI, Palmer T, Sargent F. 2009. Proteolytic processing of Escherichia coli twin-arginine signal peptides by LepB. Arch. Microbiol. 191:919-925.
25. Lyon WR, Caparon MG. 2004. Role for serine protease HtrA (DegP) of Streptococcus pyogenes in the biogenesis of virulence factors SpeB and the hemolysin streptolysin S. Infect. Immun. 72:1618-1625. (Pubitemid 38263785)
26. Magnet S, Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 105:477-498.
27. Marraffini LA, Dedent AC, Schneewind O. 2006. Sortases and the art of anchoring proteins to the envelopes of gram-positive bacteria. Microbiol. Mol. Biol. Rev. 70:192-221.
28. Murphy KC, Campellone KG, Poteete AR. 2000. PCR-mediated gene replacement in Escherichia coli. Gene 246:321-330. (Pubitemid 30190186)
29. Paetzel M, Dalbey RE, Strynadka NC. 2000. The structure and mechanism of bacterial type I signal peptidases. A novel antibiotic target. Pharmacol. Ther. 87:27-49. (Pubitemid 30618986)
30. Paetzel M, Goodall JJ, Kania M, Dalbey RE, Page MG. 2004. Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor. J. Biol. Chem. 279:30781-30790. (Pubitemid 38938011)
31. Paetzel M, Karla A, Strynadka NC, Dalbey RE. 2002. Signal peptidases. Chem. Rev. 102:4549-4580.
32. Poquet I, et al. 2000. HtrA is the unique surface housekeeping protease in Lactococcus lactis and is required for natural protein processing. Mol. Microbiol. 35:1042-1051. (Pubitemid 30137774)
33. Rand KH, Houck HJ, Brown P, Bennett D. 1993. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob. Agents Chemother. 37:613-615. (Pubitemid 23072613)
34. Roberts TC, Schallenberger MA, Liu J, Smith PA, Romesberg FE. 2011. Initial efforts toward the optimization of arylomycins for antibiotic activity. J. Med. Chem. 54:4954-4963.
35. Roberts TC, Smith PA, Cirz RT, Romesberg FE. 2007. Structural and initial biological analysis of synthetic arylomycin A2. J. Am. Chem. Soc. 129:15830-15838.
36. Roberts TC, Smith PA, Romesberg FE. 2011. Synthesis and biological characterization of arylomycin B antibiotics. J. Nat. Prod. 74:956-961.
37. Robinson C, et al. 2011. Transport and proofreading of proteins by the twin-arginine translocation (Tat) system in bacteria. Biochim. Biophys. Acta 1808:876-884.
38. Rusch SL, Kendall DA. 2007. Interactions that drive Sec-dependent bacterial protein transport. Biochemistry 46:9665-9673. (Pubitemid 47328572)
39. Sarvas M, Harwood CR, Bron S, van Dijl JM. 2004. Post-translocational folding of secretory proteins in Gram-positive bacteria. Biochim. Biophys. Acta 1694:311-327. (Pubitemid 39535077)
40. Schallenberger MA, Niessen S, Shao C, Fowler BJ, Romesberg FE. 2012. Type I signal peptidase and protein secretion in Staphylococcus aureus. J. Bacteriol. 194:2677-2686.
41. Schimana J, et al. 2002. Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp. Tu 6075. I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. (Tokyo) 55:565-570. (Pubitemid 34752601)
42. Sibbald MJ, et al. 2006. Mapping the pathways to staphylococcal pathogenesis by comparative secretomics. Microbiol. Mol. Biol. Rev. 70:755-788. (Pubitemid 44484692)
43. Silver LL. 2007. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. 6:41-55. (Pubitemid 46020285)
44. Smith PA, Powers ME, Roberts TC, Romesberg FE. 2011. In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci. Antimicrob. Agents Chemother. 55:1130-1134.
45. Smith PA, Roberts TC, Romesberg FE. 2010. Broad spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations. Chem. Biol. 17:1223-1231.
46. Smitha Rao CV, Anné J. 2011. Bacterial type I signal peptidases as antibiotic targets. Future Microbiol. 6:1279-1296.
47. Song C, Kumar A, Saleh M. 2009. Bioinformatic comparison of bacterial secretomes. Genomics Proteomics Bioinformatics 7:37-46.
48. Sriraman K, Jayaraman G. 2008. HtrA is essential for efficient secretion of recombinant proteins by Lactococcus lactis. Appl. Environ. Microbiol. 74:7442-7446. (Pubitemid 352773588)
49. Straus SK, Hancock RE. 2006. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758:1215-1223. (Pubitemid 44436068)
50. Talbot GH, et al. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668. (Pubitemid 43271379)
51. Tan YX, Romesberg FE. Latent antibiotics and the potential of the arylomycins for broad-spectrum antibacterial activity. MedChemComm. doi:10.1039/C2MD20043K.
52. van Stelten J, Silva F, Belin D, Silhavy TJ. 2009. Effects of antibiotics and a proto-oncogene homolog on destruction of protein translocator SecY. Science 325:753-756.
53. Yeh P, Tschumi AI, Kishony R. 2006. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38:489-494.